Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Research & Development (2016 - 2026)

Ani Pharmaceuticals' Research & Development history spans 16 years, with the latest figure at $12.3 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 26.34% to $12.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $51.7 million, a 15.89% increase, with the full-year FY2025 number at $51.7 million, up 15.89% from a year prior.
  • Research & Development hit $12.3 million in Q4 2025 for Ani Pharmaceuticals, roughly flat from $12.3 million in the prior quarter.
  • Over the last five years, Research & Development for ANIP hit a ceiling of $16.6 million in Q4 2024 and a floor of $2.5 million in Q3 2021.
  • Historically, Research & Development has averaged $8.2 million across 5 years, with a median of $7.5 million in 2022.
  • Biggest five-year swings in Research & Development: plummeted 53.22% in 2021 and later surged 211.77% in 2022.
  • Tracing ANIP's Research & Development over 5 years: stood at $3.1 million in 2021, then skyrocketed by 66.31% to $5.2 million in 2022, then soared by 88.95% to $9.9 million in 2023, then surged by 68.7% to $16.6 million in 2024, then decreased by 26.34% to $12.3 million in 2025.
  • Business Quant data shows Research & Development for ANIP at $12.3 million in Q4 2025, $12.3 million in Q3 2025, and $16.5 million in Q2 2025.